AEZS News 1.14 08/04/2014 04:28:37 Aeterna Zentaris (AEZS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aeterna Zentaris (AEZS) 1.14 $AEZS

Aeterna Zentaris to Announce Second Quarter 2014 Financial and Operating Results on August 7, 2014
CNW Group - Thu Jul 31, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" will announce its second quarter 2014 financial and operating results after market close on Thursday, August 7, 2014. The Company will host a conference call to discuss these results on Friday, August 8, 2014, at 8:30 a.m. eastern time.

Equities to Watch in the Health Care Sector -- ImmunoCellular Therapeutics, Aeterna Zentaris, Lexicon Pharma, BioDelivery Sciences Intl., and Jazz Pharma
PR Newswire - Wed Jul 23, 7:40AM CDT
On Tuesday, July 22, 2014, the NASDAQ Composite ended at 4,456.02, up 0.71%, the Dow Jones Industrial Average finished the day 0.36% higher at 17,113.54, and the S&P 500 closed at 1,983.53, up 0.50%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 713.75, up 0.83%, with the index also advancing 5.99% in the previous three months. Investor-Edge has initiated coverage on the following equities: ImmunoCellular Therapeutics Ltd (NYSE MKT: IMUC), Aeterna Zentaris Inc. (NASDAQ: AEZS), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), BioDelivery Sciences International Inc. (NASDAQ: BDSI), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Free research on these five companies can be accessed at:

Traders Get Bullish on Shares of AEterna Zentaris, Shares Up 6.6% (AEZS)
Comtex SmarTrend(R) - Wed Jul 02, 10:09AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing low-priced stocks, up 6.6% to $1.29 on 7.0x average daily volume. AEterna Zentaris has traded 2.7 million shares thus far today, vs. average volume of 386,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's 0.1%) and outperformed the S&P 500 (6.6% to the S&P's 0.1%) during today's trading.

Chronic Urticaria Or Hives - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nwxvjx/chronic_urticaria) has announced the addition of the "Chronic Urticaria Or Hives - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Urticaria Or Hives, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Genentech, Inc. - Merck & Co., Inc. - Biofrontera AG - AEterna Zentaris Inc. - ELORAC, Inc. For more information visit http://www.researchandmarkets.com/research/nw..._urticaria

Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto
CNW Group - Wed Jun 11, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced that the Company's Chairman, CEO, David Dodd, will be presenting a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, June 18, 2014, at 11:30 am (Eastern), in Room A-B, 4(th) floor of the Toronto Board of Trade in Toronto, Canada.

Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a Commercially Operating Specialty Biopharmaceutical Company
CNW Group - Tue Jun 10, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced the roll-out of a global resources optimization program as the Company pursues its strategy of transitioning into a commercially operating specialty biopharmaceutical company. Initiated earlier this year, the program's goal is to streamline R&D activities and increase commercial operations and flexibility. With the implementation of the global resources optimization program, the Company expects to have approximately 65 employees by year-end, as compared to 90 employees at the beginning of 2014. Due to the nature of certain proceedings, the Company intends to provide an estimate of the anticipated global restructuring charges and future cost savings as and when the financial and accounting implications of the global resources optimization program become better defined.

Aeterna Zentaris: Poster Presented at ASCO Meeting on the Design of the Current ZoptEC Phase 3 Trial in Endometrial Cancer
PR Newswire - Mon Jun 02, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the "Company" today announced that a poster was presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. The poster #TPS5630 titled, "ZoptEC: Phase 3 study of zoptarelin doxorubicin (AEZS-108)in platinum-taxane pretreated endometrial cancer (Study AEZS-108-050)", D.S.Miller, H. Gabra, G. Emons, D. S. McMeekin, A. M. Oza, S. M. Temkin, I. Vergote, was presented over the weekend by lead investigator, David S. Miller, MD, of the University of Texas Southwestern Medical Center, in Dallas, during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Currently, more than 100 sites are in operation and some160 patients have been recruited for this ZoptEC Phase 3 trial.

Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in Endometrial Cancer with Zoptarelin Doxorubicin at ASCO
CNW Group - Thu May 22, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that a poster will be presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. The poster will be presented by lead investigator, David S. Miller MD, of the University of Texas Southwestern Medical Center in Dallas, during the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held May 30-June 4, 2014 in Chicago. There are currently over 100 sites in operation and over 150 patients have been recruited for this ZoptEC Phase 3 trial.

Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego
CNW Group - Tue Apr 01, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California.

Aeterna Zentaris Announces Effectiveness of $50 Million Shelf Registration Statement for "At-the-Market" Common Share Issuance Programs
PR Newswire - Fri Mar 28, 4:23PM CDT
All amounts are in US dollars

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2013 Financial and Operating Results
PR Newswire - Thu Mar 20, 3:30PM CDT
All amounts are in US dollars

Stock to Watch: AEterna Zentaris Down 10.1% (AEZS)
Comtex SmarTrend(R) - Wed Mar 12, 10:13AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's worst performing low-priced stocks, down 10.1% to $1.34 on 1.2x average daily volume. Thus far today, AEterna Zentaris has traded 1.3 million shares, vs. average volume of 1.1 million shares per day. The stock has underperformed the Dow (-10.1% to the Dow's -0.2%) and underperformed the S&P 500 (-10.1% to the S&P's -0.2%) during today's trading.

Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2013 Financial and Operating Results on March 20, 2014
CNW Group - Wed Mar 12, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" will announce its fourth quarter and full-year 2013 financial and operating results after market close on Thursday, March 20, 2014. The Company will host a conference call to discuss these results on Friday, March 21, 2014, at 8:30 a.m., Eastern Time.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 51

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Automus and Google Cloud Put Agents to Work on Oracle

Updated Category News Views 96

Oracle back offices are where shiny AI promises go to earn their keep, or get buried under a mountain of integrations. Automus Consulting’s newly announced collaboration with Google Cloud, unveiled November 20 at Oracle AI World, is aimed squarely at that messy middle. The firm wants to combine its Oracle implementation experience with Google Cloud infrastructure and...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 67

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Rosalind Franklin University’s $23.8M Scholarship Win

Updated Category News Views 80

Twenty-three million dollars can disappear fast in graduate health education, which is exactly why Rosalind Franklin University’s campaign result deserves more than a polite round of applause. The university’s five-year Empowering Scholars effort closed in June 2026 with $23,836,272 raised, clearing its $20 million target by roughly 19%. In a world where institutions...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Cedars-Sinai and nference Build a Living Data Engine

Updated Category News Views 175

Five million patient histories are not a flashy product demo. They are a serious raw-material advantage, provided the data can be protected, organized, and made useful without turning clinical research into a carnival of loose claims. That is the real weight behind nference's long-term collaboration with Cedars-Sinai, announced November 20, 2026. The pair plan to build a...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 67

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
CITGO Sign Return Caps Kenmore's Careful Rebuild Work

Updated Category News Views 79

Thirty feet upward and 120 feet eastward is not the sort of move that usually stops a city in its tracks, yet Boston’s CITGO Sign was never merely rooftop hardware. Its public relighting in Kenmore Square marks the final phase of the redevelopment at 660 Beacon Street, and the real accomplishment is less flashy than the lights: a beloved, federally landmarked object...

Continue Reading

Top 5 Most Recently Viewed Articles

Epic Yoga Event by Real Essentials to Support Ovarian Cancer

Updated Category News Views 70

Real Essentials Teams Up for Ovarian Cancer Awareness To honor Ovarian Cancer Awareness Month, Real Essentials, a brand celebrated for its affordable yet high-quality apparel, partnered with Not These Ovaries, a nonprofit organization dedicated to ovarian cancer. Together, they created a unique yoga event that aimed to raise both awareness and funds for essential ovarian...

Continue Reading
MKDWELL Tech Inc. Posts H1 2024 Financial Results Drop

Updated Category News Views 115

MKDWELL Tech Inc. Financial Overview for 2024 MKDWELL Tech Inc. (NASDAQ: MKDW), a key player in the automotive electronics industry with operations in Mainland China and Taiwan, has provided an update on its financial status for the first half of the fiscal year. The latest results show a significant decline in revenue compared to the same period in the previous year....

Continue Reading
Northwest Pipe Company Strengthens Production with New Facility

Updated Category News Views 212

Northwest Pipe Company Enhances Production Capacity Northwest Pipe Company, renowned for its expertise in water-related infrastructure, has announced a significant upgrade to its production facilities. The company has recently inaugurated a new precast concrete pipe and manhole manufacturing plant aimed at addressing the rising demand in the region. With this strategic...

Continue Reading
Allient Inc. Posts Third Quarter Gains Driven by Initiatives

Updated Category News Views 99

Allient Inc. Announces Impressive Third Quarter Results Allient Inc. (NASDAQ: ALNT), a global leader in precision and specialty Motion, Controls and Power products, has announced significant financial results for its third quarter. Despite facing challenges in key industrial and vehicle markets, the company has demonstrated resilience through its operational improvements...

Continue Reading
Fulcrum Therapeutics Investor Event to Unveil PIONEER Findings

Updated Category News Views 191

Introduction to Fulcrum Therapeutics Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a pioneering biopharmaceutical company, is dedicated to enhancing the lives of individuals grappling with genetically defined rare diseases. Their primary focus is on developing innovative small molecules that target specific diseases at their root cause. This commitment drives their latest...

Continue Reading